跳到正文
原文
Endpoints News 生物医药· Kyle LaHucik·· 2026-10-08AI 评分26

Ultragenyx 以 2.1 亿美元出售 PRV 并保留一项待变现

Ultragenyx sells PRV for $210M and still has another to monetize

AI 导读

Ultragenyx Pharmaceutical 正在以 2.1 亿美元的价格向未披露的买家出售一张优先审评券(PRV),这是其最丰厚的销售之一。该公司目前仍持有另一张 PRV 可供变现。

正文

Ul­tragenyx Phar­ma­ceu­ti­cal is sell­ing a pri­or­i­ty re­view vouch­er to an undis­closed buy­er for $210 mil­lion, mark­ing one of the rich­est sales …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news